Voyager Therapeutics, Inc.
CENTRAL NERVOUS SYSTEM TARGETING POLYNUCLEOTIDES

Abstract:

The present disclosure relates to compositions, methods and processes for the formulation and for the administration of a gene therapy agent using parvovirus e.g., adeno-associated virus (AAV) to the CNS, CNS tissues, CNS structures or CNS cells.